Search results
Results From The WOW.Com Content Network
Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumour (PEComa).
mTOR inhibitors are a class of drugs used to treat several human diseases, including cancer, autoimmune diseases, and neurodegeneration. They function by inhibiting the mammalian target of rapamycin (mTOR) (also known as the mechanistic target of rapamycin), which is a serine/threonine-specific protein kinase that belongs to the family of phosphatidylinositol-3 kinase (PI3K) related kinases ...
Since 1915, food waste has been identified as a considerable problem and has been the subject of ongoing media attention, intensifying with the launch of the "Love Food, Hate Waste" campaign in 2007. Food waste has been discussed in newspaper articles, news reports and television programmes, which have increased awareness of it as a public issue.
I’ve eaten outside in many restaurants. It’s just very hard to do in Boston in the wintertime,” Sax said. ... What might be safe for a healthy 30-year-old could be way too unsafe for a frail ...
Articles related to waste management include: A. Advanced Thermal Treatment ...
A big part of waste management deals with municipal solid waste, which is created by industrial, commercial, and household activity. [4] Waste management practices are not the same across countries (developed and developing nations); regions (urban and rural areas), and residential and industrial sectors can all take different approaches. [5]
Yoo, Young Ji; Hwang, Jae-yeon; Shin, Hea-luyung; Cui, Heqing; Lee, Jinwon; Yoon, Yeo Joon (26 November 2014). "Characterization of negative regulatory genes for the biosynthesis of rapamycin in Streptomyces rapamycinicus and its application for improved production". Journal of Industrial Microbiology & Biotechnology. 42 (1): 125–135.
NHS England has been criticised for delays in deciding on a policy for the prescription of everolimus in the treatment of Tuberous Sclerosis. 20 doctors addressed a letter to the board in support of the charity Tuberous Sclerosis Association saying " around 32 patients with critical need, whose doctors believe everolimus treatment is their best or only option, have no hope of access to funding.